Clinical Trial Update: Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and tolerability of intravenous doses of activated recombinant human factor VII in healthy volunteers. The study sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Hemophilia with Inhibitors

Drugs mentioned

• NovoSeven RT (Recombinant activated factor VII)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 1 | Status: COMPLETED